Replies to post #391064 on Innovation Pharmaceuticals Inc (IPIX)

[jimvette]

Article just published about Brilacidin’s effectiveness in fighting COVID !
Thanks Frenchbroad for finding this !
GO IPIX !!!

[steelyeye]

Yes, I see this was published only about one week ago, on June 30, 2022.

Thank you for sharing it.

"In the need of reinforcing the drug repositioning strategy
and developing specific SARS-CoV-2 treatment, recently,
three main groups of scientists discovered that a new
antibacterial drug, named brilacidin, provides attractive
benefits against SARS-CoV-2, and specifically without
major side effects.
This previous findings were confirmed by Xu, et al. [2],
who further, specified that the protective effect of brilacidin
is more likely to be preventive than curative, as brilacidin
has no inhibition/protective effect after SARS-CoV-2-cell
attachment, but only can inhibit SARS-CoV-2 entry into
cells.
Furthermore, while Xu, et al. [2] demonstrated the
effectiveness of brilacidin against SARS-CoV-2 and its
derivative variants including P.1 and B.1.1.7 strains, Hu, et
al. [3] discovered that brilacidin protective activity has a
broader spectrum to other sarbecoviruses, including OC43,
229E, and NL63 strains.
Highlights
1. Brilacidin protects cells from SARS-Co-2 infection,
at low dose.
2. Brilacidin has a broad-spectrum antiviral activity
against multiple Human Coronaviruses (HCoVs)
including SARS-CoV-2 and its derivatives, HCoV-
229E, HCoV-OC43, and HCoV-NL63.
3. Brilacidin has a dual antiviral mechanism of
action, including virucidal activity and binding to
coronavirus attachment factor HSPGs on the host
cell surface
https://www.jelsciences.com/articles/jbres1504.pdf

[cellardwellar]

Things are a changing, great find frenchbroad. Thanks

[CallMeCrazy]

Great find fb: connecting the dots

The race to develop effective therapeutics/therapies against SARS-CoV-2
infections and COVID-19 is ongoing as the pandemic is still far from being
controlled. Recently, three groups of scientists including Bakovic, et al. [1], Xu, et
al. [2]and Hu, et al. [3] respectively, reported a promising and highly attractive
antiviral activity of a new drug, named brilacidin, against SARS-CoV-2 infections.
Briefly, they discovered that brilacidin, a de novo mimetic of Host Defense Peptides
(HDPs), efficiently protects cells from infections by several strains of SARS-CoV-2
including wild type and Variant of Concern (VOCs) strains, specifically through both
a viral inactivation and a blocking of interaction of SARS-CoV-2 proteins with host
cell surface Heparan Sulfate Proteoglycans (HSPGs).

1
The second clinical school, Medical imaging, Chongqing Medical University, Chongqing, China
2
Laboratory of Structural Immunology, CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of
Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
3
Department of Radiation Oncology, Cedars Sinai Hospital, Los Angeles, USA

To sum up, these three studies demonstrated that
brilacidin, a potent antibacterial synthetic HDP mimetic
effi ciently prevents SARS-CoV-2 entry into cells through
interaction with both host cell surface HSPG and SARSCoV-2 N or M proteins to block viral attachment deactivate
viral particles, respectively, and its antiviral activity is
broaden to SARS-CoV-2 variants and other HCoVs. This
broad-spectrum dual antiviral mechanism of action, which is
enhanced when combined with Remdesivir, could break the
transmission chain of SARS-CoV-2 and reduce emergence
of SARS-CoV-2 resistant variant development.

https://www.jelsciences.com/articles/jbres1504.pdf

...Connecting the dots...

Global COVID-19 Therapeutics Market worth $14.6 billion by 2022

According to the latest market intelligence research report by InsightAce
Analytic, the global COVID-19 Therapeutics market size was valued at US$ 10.2
Billion in 2021, and it is expected to reach US$ 25.6 Billion in 2030, record
a promising CAGR of 10.7% from 2021 to 2030.

The growth of the COVID-19 Therapeutics Market is
primarily attributed the increased prevalence of COVID-19 across the globe. In
the first week of January 2022, Covid-19 cases have now been recorded in over
300 million people worldwide. The United States had over 50 million confirmed
cases and over 800,000 deaths, making it the Country with the highest death
toll. Pharmaceutical companies are investing heavily in product research due
to the rising pandemic effect, and they are focusing on the production of
enhanced therapeutics that can cure the covid-19. The market is further
supported by rising awareness about coronavirus and collective efforts by the
pharmaceutical companies and government in the development of covid-19
therapeutic drugs.

https://www.bloomberg.com/press-releases/2022-01-18/global-covid-19-therapeutics-market-worth-14-6-billion-by-2022-exclusive-report-by-insightace-analytic

I suspect/expect that things will get very interesting, very soon.

[MackG]

Thank you, frenchbroad, for the important find that is sure to get a lot of positive attention and bring in more investors at a nickel a share to IPIX. Some will buy for a quick flip, but investors who take the time to do a little research will recognize this opportunity and stay for the long run. Awesome!